biote Corp. 8-K

What Happened

• biote Corp. (BTMD) filed an 8-K reporting that Bret Christensen resigned as Chief Executive Officer of BioTE Medical, LLC effective June 8, 2026; the Board said the resignation was not due to any disagreement with the company. A Separation Agreement dated June 2, 2026 gives Christensen three months after separation to exercise vested options, keeps him on the Board as a Class III director through the 2028 Annual Meeting, and grants him a stock option to purchase 130,000 shares.
• Concurrently, the Board appointed Robert Peterson (currently BioTE’s Chief Financial Officer and Chief Business Officer) as Interim Chief Executive Officer and a director effective June 8, 2026; the Board was expanded to eight directors and Peterson will serve as a Class I director through the 2029 Annual Meeting. Separately, on June 1, 2026 the Board appointed Marc Beer as Executive Chairman effective June 8, 2026 under a Services Agreement (dated June 2, 2026) providing $521,200 base pay, up to an 85% annual bonus, and a stock option to purchase 114,157 shares, plus specified change-in-control and severance protections.

Key Details

• Bret Christensen: resignation effective June 8, 2026; Separation Agreement dated June 2, 2026; 3 months to exercise vested options; granted option for 130,000 shares; remains a Class III director until 2028 Annual Meeting.
• Robert Peterson: named Interim CEO and director effective June 8, 2026; board size increased to 8; will serve as Class I director through 2029 Annual Meeting; interim CEO pay not yet determined.
• Marc Beer: Executive Chairman effective June 8, 2026; Services Agreement provides $521,200 base, up to 85% bonus, option for 114,157 shares; change-in-control/severance includes 18 months pay continuation, COBRA premium coverage up to 18 months, and accelerated vesting of time-based awards in certain cases.
• Company issued a press release about these management changes on May 28, 2026 and filed the 8-K on June 2, 2026.

Why It Matters

• Leadership transition: The CEO role at BioTE is moving from Christensen to an internal interim leader (Peterson), which suggests continuity in operations but introduces short-term management uncertainty until a permanent CEO is named.
• Compensation and dilution: Equity grants (130,000 and 114,157 option shares) and generous cash/bonus and severance terms for the Executive Chairman may affect future share dilution and operating expenses.
• Governance impact: Christensen remains on the Board through 2028, and Peterson joins the Board through 2029, changing Board composition and director class terms—relevant for investors tracking corporate governance and succession.